Our platform combines our unique Organ-on-Chip technology, multicellular 3D disease model development, and Artificial Intelligence (AI) to provide spatiotemporal profiling and analysis of drug discovery, development, testing and treatment at a cellular level.
Our microfluidic-based Organ-on-Chip technology recapitulates the multicellular microenvironment of the organ, incorporating vascularization, biomechanical structure and forces, and paracrine signaling experienced in vivo, providing an excellent in vitro model.
Downstream morphological, secretory, and multi-omics profiling of these complex organ models using AI and machine learning analysis, allows the development of multiplexed profiles of different cellular populations, enabling the detection of subtle biologically relevant responses and phenotypes.
Cofounder
CEO
Cofounder Strategy & Investor Relations
Engineering & Product Development
Biology & Preclinical Development
Sr. Principal
Scientist
Sr Res
Assoc
Scientist II
Lab Admin
Lead
Engineer
Mechanical
Engineer
Sr Scientist
AI
Assoc Scientist
Imaging
Research
Associate
Senior
Engineer
Accountant
Engineer
Professor at Harvard Medical School
Professor
at MIT
Professor at
Northeastern
In addition to providing biologically relevant complexity, our device and platform are designed for scalability, allowing high-throughput screening and lab automation compatibility, to meet the efficiency needs of drug discovery and development. At Xellar Biosystems, we excel at complexity and scalability to accelerate the world of drug discovery and development
Leave us a request and we will contact you soon.